Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)

Analysis of Liquidity Ratios
Quarterly Data

Beginner level

Liquidity ratios measure the company’s ability to meet its short-term obligations.

Liquidity Ratios (Summary)

Bristol-Myers Squibb Co., liquidity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Current ratio 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94 1.73 1.75 1.80 1.86
Quick ratio 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44 1.28 1.30 1.35 1.38
Cash ratio 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99 0.88 0.89 0.92 0.94

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Bristol-Myers Squibb Co.’s current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Bristol-Myers Squibb Co.’s quick ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Bristol-Myers Squibb Co.’s cash ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Current Ratio

Bristol-Myers Squibb Co., current ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Current assets 40,191  37,716  17,093  17,160  14,869  13,874  14,649  14,854  15,048  14,324  13,615  13,704  13,204  12,298  11,215  10,415  12,926  13,056  14,925  14,608  14,177  14,062  14,014 
Current liabilities 10,489  9,711  8,841  10,654  9,694  9,878  9,624  9,563  9,438  9,017  8,494  8,841  8,996  7,885  7,597  8,017  7,158  7,435  7,689  8,461  8,103  7,798  7,521 
Liquidity Ratio
Current ratio1 3.83 3.88 1.93 1.61 1.53 1.40 1.52 1.55 1.59 1.59 1.60 1.55 1.47 1.56 1.48 1.30 1.81 1.76 1.94 1.73 1.75 1.80 1.86
Benchmarks
Current Ratio, Competitors2
Abbott Laboratories 1.54 1.68 1.58 1.62 1.42 1.58 1.66 2.26 2.69 2.94 2.91 4.02 1.56 1.50 1.48 1.54 1.82 2.30 2.17 1.45 1.52 1.85 1.76
AbbVie Inc. 1.15 0.89 1.04 0.98 1.20 0.80 1.20 1.28 1.45 1.38 1.76 1.65 1.79 1.81 1.56 1.50 2.03 1.50 1.39 1.41 2.65 2.82 2.79
Allergan PLC 1.00 1.03 0.71 1.13 0.92 1.00 1.10 1.16 1.18 1.21 1.32 2.27 3.95 0.99 0.99 1.03 2.05 1.37 1.44 1.37 1.40 1.98 1.51
Amgen Inc. 2.89 2.89 2.77 2.79 3.08 3.39 3.88 5.49 6.07 6.20 4.41 4.11 4.35 3.97 4.95 4.44 5.42 5.48 5.53 4.95 4.22 4.36 3.45
Biogen Inc. 1.91 2.46 2.84 2.32 2.75 2.36 3.23 2.34 2.19 2.10 2.29 2.55 3.24 2.96 2.59 2.60 3.52 2.20 2.70 2.11 2.25 2.05 2.21
Eli Lilly & Co. 1.17 1.13 1.12 1.73 1.91 1.40 1.41 1.32 1.38 1.39 1.24 1.37 1.62 1.54 1.60 1.53 1.51 1.50 1.41 1.09 1.60 1.77 1.97
Gilead Sciences Inc. 2.96 3.76 3.62 3.38 3.45 3.00 2.84 2.74 3.68 3.37 2.59 2.22 1.93 1.76 1.77 2.50 2.77 2.03 2.70 3.07 2.07 2.49 2.19
Johnson & Johnson 1.26 1.33 1.44 1.47 1.72 1.65 1.58 1.41 1.32 1.34 2.52 2.47 2.73 3.08 2.83 2.17 2.51 2.49 2.44 2.36 2.61 2.47 2.41
Merck & Co. Inc. 1.26 1.21 1.37 1.17 1.44 1.33 1.42 1.33 1.43 1.50 1.59 1.78 1.89 1.87 1.64 1.55 1.62 1.62 1.61 1.77 1.34 1.87 1.84
Pfizer Inc. 0.90 1.47 1.54 1.57 1.43 1.16 1.27 1.35 1.43 1.34 1.44 1.25 1.11 1.37 1.44 1.49 1.62 2.14 2.45 2.67 2.86 2.66 2.33
Regeneron Pharmaceuticals Inc. 4.03 3.88 4.58 4.47 4.04 3.62 3.59 3.82 3.63 3.75 2.80 2.56 3.64 3.37 3.41 3.59 3.64 3.80 4.31 3.31 5.36 5.46 6.13
Vertex Pharmaceuticals Inc. 3.44 3.74 3.78 3.43 3.71 3.67 3.68 3.28 3.28 3.49 3.82 2.31 2.08 2.33 2.54 2.78 3.63 3.46 4.49 4.20 4.43 3.71 3.83
Zoetis Inc. 4.39 4.17 4.05 3.60 4.06 4.38 4.27 3.85 2.80 2.01 1.96 3.03 3.24 3.20 2.84 2.15 2.08 2.11 2.27 3.19 3.36 3.14 2.86

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 40,191 ÷ 10,489 = 3.83

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Current ratio A liquidity ratio calculated as current assets divided by current liabilities. Bristol-Myers Squibb Co.’s current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019.

Quick Ratio

Bristol-Myers Squibb Co., quick ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 30,489  28,404  7,335  6,911  5,408  4,999  5,342  5,421  4,644  3,470  3,910  4,237  3,432  2,934  2,644  2,385  3,975  4,199  6,294  5,571  4,851  4,282  5,225 
Marketable securities 2,053  953  1,429  1,973  1,422  1,076  1,428  1,391  2,478  3,035  2,199  2,113  2,128  1,717  1,663  1,885  1,438  1,277  1,313  1,864  2,370  2,893  1,834 
Receivables 5,510  5,667  5,704  5,965  5,871  5,559  5,683  6,300  5,922  5,782  5,494  5,543  5,597  5,622  4,957  4,299  3,908  3,672  3,458  3,390  3,321  3,315  3,316 
Total quick assets 38,052  35,024  14,468  14,849  12,701  11,634  12,453  13,112  13,044  12,287  11,603  11,893  11,157  10,273  9,264  8,569  9,321  9,148  11,065  10,825  10,542  10,490  10,375 
 
Current liabilities 10,489  9,711  8,841  10,654  9,694  9,878  9,624  9,563  9,438  9,017  8,494  8,841  8,996  7,885  7,597  8,017  7,158  7,435  7,689  8,461  8,103  7,798  7,521 
Liquidity Ratio
Quick ratio1 3.63 3.61 1.64 1.39 1.31 1.18 1.29 1.37 1.38 1.36 1.37 1.35 1.24 1.30 1.22 1.07 1.30 1.23 1.44 1.28 1.30 1.35 1.38
Benchmarks
Quick Ratio, Competitors2
Abbott Laboratories 0.93 0.98 0.94 1.03 1.00 0.94 1.04 1.67 2.02 2.13 2.01 3.31 0.94 0.92 0.88 1.04 1.10 1.60 1.45 0.76 0.78 1.13 1.07
AbbVie Inc. 0.92 0.64 0.78 0.78 0.95 0.55 0.90 0.89 1.11 0.98 1.24 1.14 1.42 1.41 1.25 1.21 1.57 1.12 1.10 1.06 2.10 2.21 2.05
Allergan PLC 0.79 0.61 0.51 0.83 0.65 0.73 0.80 0.95 0.96 1.00 1.11 2.00 3.71 0.34 0.48 0.42 0.52 0.78 0.80 0.52 0.57 1.40 0.62
Amgen Inc. 2.28 2.41 2.37 2.44 2.68 2.94 3.42 4.98 5.46 5.47 3.96 3.68 3.90 3.52 4.44 3.97 4.75 4.76 4.68 4.22 3.56 3.67 2.72
Biogen Inc. 1.57 1.70 2.07 1.83 2.19 1.79 2.67 1.78 1.62 1.49 1.57 1.94 2.44 2.16 1.91 1.93 2.84 1.57 1.98 1.54 1.66 1.49 1.60
Eli Lilly & Co. 0.66 0.67 0.65 1.20 1.36 0.96 0.87 0.91 0.94 0.92 0.78 0.98 1.06 1.00 0.98 1.04 1.01 1.01 0.95 0.77 1.11 1.20 1.35
Gilead Sciences Inc. 2.74 3.41 3.32 3.15 3.16 2.70 2.60 2.52 3.39 3.01 2.19 1.78 1.57 1.39 1.33 2.07 2.33 1.56 2.17 2.56 1.51 1.96 1.64
Johnson & Johnson 0.93 0.95 1.01 1.08 1.22 1.17 1.08 1.04 0.92 0.91 2.06 2.04 2.25 2.54 2.32 1.77 1.93 1.87 1.80 1.76 1.94 1.80 1.74
Merck & Co. Inc. 0.80 0.75 0.88 0.72 0.95 0.82 0.86 0.83 0.97 1.03 1.13 1.24 1.31 1.26 1.13 1.04 1.05 1.02 1.09 1.19 0.80 1.14 1.23
Pfizer Inc. 0.50 0.71 0.72 0.84 0.94 0.72 0.76 0.93 0.95 0.88 0.94 0.84 0.70 0.94 0.99 1.07 1.08 1.62 1.81 2.07 2.18 2.03 1.75
Regeneron Pharmaceuticals Inc. 3.14 2.99 3.66 3.50 3.10 2.80 2.82 2.98 2.94 3.02 2.34 2.13 3.18 2.94 2.95 3.10 3.18 3.32 3.88 2.93 4.80 4.87 5.56
Vertex Pharmaceuticals Inc. 3.20 3.51 3.54 3.19 3.46 3.41 3.39 2.94 2.92 3.06 3.30 2.06 1.81 2.02 2.19 2.41 3.12 2.97 4.17 3.97 4.28 3.58 3.71
Zoetis Inc. 2.72 2.58 2.55 2.24 2.31 2.62 2.60 2.34 1.71 0.94 0.92 1.47 1.51 1.49 1.36 1.17 0.98 0.98 1.07 1.71 1.66 1.58 1.43

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 38,052 ÷ 10,489 = 3.63

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Quick ratio A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. Bristol-Myers Squibb Co.’s quick ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.

Cash Ratio

Bristol-Myers Squibb Co., cash ratio calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Selected Financial Data (US$ in millions)
Cash and cash equivalents 30,489  28,404  7,335  6,911  5,408  4,999  5,342  5,421  4,644  3,470  3,910  4,237  3,432  2,934  2,644  2,385  3,975  4,199  6,294  5,571  4,851  4,282  5,225 
Marketable securities 2,053  953  1,429  1,973  1,422  1,076  1,428  1,391  2,478  3,035  2,199  2,113  2,128  1,717  1,663  1,885  1,438  1,277  1,313  1,864  2,370  2,893  1,834 
Total cash assets 32,542  29,357  8,764  8,884  6,830  6,075  6,770  6,812  7,122  6,505  6,109  6,350  5,560  4,651  4,307  4,270  5,413  5,476  7,607  7,435  7,221  7,175  7,059 
 
Current liabilities 10,489  9,711  8,841  10,654  9,694  9,878  9,624  9,563  9,438  9,017  8,494  8,841  8,996  7,885  7,597  8,017  7,158  7,435  7,689  8,461  8,103  7,798  7,521 
Liquidity Ratio
Cash ratio1 3.10 3.02 0.99 0.83 0.70 0.62 0.70 0.71 0.75 0.72 0.72 0.72 0.62 0.59 0.57 0.53 0.76 0.74 0.99 0.88 0.89 0.92 0.94
Benchmarks
Cash Ratio, Competitors2
Abbott Laboratories 0.41 0.37 0.36 0.45 0.59 0.36 0.45 1.08 1.41 1.45 1.33 2.82 0.54 0.51 0.47 0.67 0.70 1.22 1.07 0.42 0.45 0.72 0.69
AbbVie Inc. 0.61 0.32 0.38 0.47 0.57 0.22 0.56 0.59 0.73 0.59 0.71 0.66 0.87 0.86 0.81 0.77 1.05 0.74 0.72 0.73 1.56 1.62 1.46
Allergan PLC 0.47 0.24 0.20 0.33 0.19 0.28 0.35 0.65 0.64 0.67 0.86 1.68 3.41 0.06 0.22 0.13 0.25 0.20 0.28 0.05 0.08 1.03 0.11
Amgen Inc. 1.94 2.05 2.07 2.17 2.41 2.62 3.07 4.62 5.05 5.02 3.65 3.40 3.60 3.23 4.08 3.62 4.34 4.35 4.28 3.86 3.28 3.33 2.41
Biogen Inc. 1.00 0.92 1.24 1.07 1.39 1.02 1.88 1.10 1.02 0.86 0.96 1.43 1.73 1.51 1.29 1.33 2.22 0.93 1.11 0.83 0.96 0.82 0.79
Eli Lilly & Co. 0.15 0.20 0.19 0.68 0.83 0.53 0.41 0.55 0.55 0.48 0.34 0.55 0.51 0.47 0.41 0.54 0.52 0.51 0.50 0.43 0.64 0.69 0.79
Gilead Sciences Inc. 2.39 3.03 2.97 2.84 2.81 2.38 2.25 2.19 2.96 2.48 1.70 1.29 1.11 0.84 0.76 1.48 1.68 0.96 1.52 1.76 1.04 1.41 1.09
Johnson & Johnson 0.51 0.49 0.53 0.63 0.71 0.66 0.56 0.60 0.51 0.45 1.57 1.59 1.74 1.98 1.80 1.38 1.48 1.39 1.31 1.32 1.44 1.30 1.23
Merck & Co. Inc. 0.39 0.35 0.47 0.40 0.55 0.42 0.43 0.46 0.58 0.64 0.77 0.83 0.84 0.79 0.74 0.70 0.69 0.65 0.76 0.84 0.55 0.75 0.91
Pfizer Inc. 0.25 0.40 0.39 0.59 0.59 0.42 0.42 0.66 0.60 0.53 0.59 0.57 0.41 0.65 0.68 0.79 0.74 1.25 1.37 1.67 1.68 1.55 1.37
Regeneron Pharmaceuticals Inc. 1.63 1.56 2.14 1.95 1.55 1.26 1.28 1.24 1.21 1.23 1.00 0.84 1.47 1.10 0.92 1.29 1.22 1.00 1.38 1.38 2.54 2.32 2.12
Vertex Pharmaceuticals Inc. 2.88 3.14 3.14 2.83 3.08 2.98 2.99 2.59 2.55 2.67 2.88 1.81 1.56 1.72 1.86 2.06 2.68 2.72 3.91 3.77 3.97 3.36 3.55
Zoetis Inc. 1.74 1.66 1.66 1.39 1.39 1.61 1.65 1.43 1.13 0.40 0.36 0.65 0.63 0.63 0.58 0.65 0.36 0.35 0.41 0.81 0.60 0.54 0.45

Based on: 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28), 10-K (filing date: 2015-02-13), 10-Q (filing date: 2014-10-24), 10-Q (filing date: 2014-07-24), 10-Q (filing date: 2014-04-29).

1 Q3 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 32,542 ÷ 10,489 = 3.10

2 Click competitor name to see calculations.

Liquidity ratio Description The company
Cash ratio A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. Bristol-Myers Squibb Co.’s cash ratio improved from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.